Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only
| Attribute | ||
|---|---|---|
Research Summary | MOTS-c is known as the "exercise in a bottle" peptide. It targets your muscles and tells them to process sugar and burn fat as if you were running a marathon, boosting massive stamina and energy. | Imagine your cells have a tiny engine that burns fat, but sometimes a heavy brake gets stuck on it. 5-Amino-1MQ removes that brake so your cells can burn energy faster and shrink fat cells without you having to eat less. |
Studied For | Metabolic homeostasisInsulin resistance / obesityExercise-mimetic researchAMPK activationGlucose metabolismSkeletal muscle uptakeLongevity and agingInflammation regulationMitochondrial stress responseObesity researchType 2 diabetes modelsMenopause-related metabolic changesNAD metabolismFolate-methionine cycleMitochondrial communicationPhysical endurance researchMetabolic flexibilitymetabolic regulationenergy boostAMPK activatorweight lossinsulin sensitivityexercise endurancemitochondrial function | Obesity / metabolic syndromeFat-loss / energy-expenditure researchNAD+ metabolism enhancementNNMT inhibitionAdipogenesis inhibitionAdipocyte differentiation blockingLean mass preservationInsulin sensitivity improvementLipid metabolismDiet-induced obesity modelsWeight management without appetite suppressionSAM (S-adenosyl methionine) pool preservationEpigenetic metabolic regulationMitochondrial efficiencyExercise performancefat burningmetabolism boosterweight lossmuscle wasting preventioncellular energyanti-agingNAD+ salvage pathway |
Research Areas | MetabolicMitochondrial FunctionPerformance & MuscleWeight Management & Fat LossLongevity | MetabolicWeight Management & Fat LossMitochondrial FunctionPerformance & Muscle |
Best Stacked With | nad-plusss-31aicarl-carnitinebac-water | nad-plusmots-cl-carnitinebac-water |
Overview | ||
Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
Compound Class | Mitochondrial-derived peptide (MDP) encoded within 12S rRNA of mitochondrial genome | Small-molecule NNMT inhibitor (quinolinium salt); not a peptide |
Molecular Target | AMPK activation; folate-methionine cycle; AICAR-independent AMPK signaling; nuclear translocation for gene expression regulation | Nicotinamide N-methyltransferase (NNMT) inhibition; preserves SAM and NAD+ pools; reduces adipogenesis; enhances energy expenditure |
Aliases / AKA | Mitochondrial ORF of 12S rRNA type-cMOTS cMOTS-c peptideMitochondrial peptide MOTS-cMitokine MOTS-c12S rRNA-encoded peptide | 5-Amino-1-methylquinolinium5A1MQ5-amino-1-methylquinolinium saltNNMT inhibitor 5-amino-1mqNicotinamide N-methyltransferase inhibitor5-amino 1MQ |
Parent Compound | Mitochondrial MT-RNR1 | 1-methylnicotinamide mimic |
Molecular Weight | 2174.6 Da | 159.21 Da |
Amino Acid Sequence | MRWQEMGYIFYPRKLR | small molecule (quinolinium) |
CAS Number | 1627580-64-6 | 685079-15-6 (iodide salt) |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 244 Good | 152 Moderate |
Clinical Trials | 66 Active | Not Listed |
Regulatory Status | Not FDA-approved; research chemical; WADA-prohibited (2024). | Not approved; research chemical. |
Evidence & Regulatory | ||
Half-Life | ~30 minutes | ~4 hours |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | Mouse and in vitro studies show improved metabolic homeostasis and reduced obesity and insulin resistance. Controlled human therapeutic trials are lacking. | Diet-induced-obese mice showed reduced body weight and fat mass without changed food intake. There are no completed published human trials; all claims are animal or in vitro. Preliminary. |
Side Effects Noted | No well-characterized human adverse-event profile; human safety is not established. | No adverse effects in short rodent studies; essentially no human safety data; chronic effects on the methylation pool are uncharacterized. |
Warnings | Not approved. WADA-prohibited effective 2024 (relevant for competitive athletes). Evidence is predominantly preclinical. Research use only. | Strictly investigational with no human approval and no defined human dose. CAS and salt form should be verified against a supplier certificate of analysis. |
Pharmacology | ||
Form | lyophilized | solid (iodide salt) |
Diluent | bacteriostatic or sterile water | water or DMSO for stock |
Storage Temp | frozen/refrigerated, dark | cold, desiccated, dark |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | Two methionines are oxidation-prone. | Prepare fresh. |
Reconstituted Shelf Life | 28 Days Refrigerated | 28 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.
